Elevated levels of head activator in human brain tumors and in serum of patients with brain and other neurally derived tumors
✍ Scribed by H. C. Schaller; E. Schilling; L. Theilmann; H. Bodenmüller; W. Sachsenheimer
- Publisher
- Springer US
- Year
- 1988
- Tongue
- English
- Weight
- 426 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0167-594X
No coin nor oath required. For personal study only.
✦ Synopsis
In normal human tissue high concentrations of the neuropeptide head activator are found in the hypothalamus, in the retina, and in the gastro-intestinal tract. Up to 100-fold elevated levels of head activator over neighbouring tissue were found in tumors of the brain, especially in tumors of neural origin like astrocytoma and glioblastoma, but also in meningioma. Coincident with elevated tissue levels, an increased secretion into the general circulation was observed. Elevated levels of head activator in the blood were also observed in patients with tumors in peripheral locations, especially in tumors of gastrointestinal tract and/or of neuroendocrine origin. After tumor removal, the head activator levels in the blood dropped to normal values suggesting a possible role of head activator in neuroendocrine tumorigenesis.
📜 SIMILAR VOLUMES
CSF beta-glucuronidase, polyamines and carcinoembryonic antigen (CEA) were analyzed in 16 patients with meningeal carcinomatosis from solid tumor in systemic organs, 27 with benign brain lesions, 18 with primary brain tumors, 14 with metastatic brain tumors and 5 with leptomeningeal dissemination of
Pre-clinical data and adult experience suggests that topoisomerase targeted anti-cancer agents may be highly schedule dependent, and efficacy may improve with prolonged exposure. To investigate this hypothesis, 28 children with recurrent brain and solid tumors were enrolled in a phase II study of or
Complement levels (CH,,, C,, C, and C1,) were determined in sera of 90 healthy subjects and 200 cancer patients. Complement levels of cancer patients were significantly higher than those of the healthy subjects, but there was a stagelinked increase of complement levels. Patients in remission had nea